Wave Life Sciences Ltd. (WVE)
WVE Stock Price Chart
Explore Wave Life Sciences Ltd. interactive price chart. Choose custom timeframes to analyze WVE price movements and trends.
WVE Company Profile
Discover essential business fundamentals and corporate details for Wave Life Sciences Ltd. (WVE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Nov 2015
Employees
317.00
Website
https://wavelifesciences.comCEO
Paul Bolno
Description
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
WVE Financial Timeline
Browse a chronological timeline of Wave Life Sciences Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is -$0.31, while revenue estimate is $7.45m.
Earnings released on 28 Apr 2026
EPS came in at -$0.13 surpassing the estimated -$0.34 by +61.76%, while revenue for the quarter reached $38.25m , beating expectations by +352.57%.
Earnings released on 26 Feb 2026
EPS came in at -$0.30 falling short of the estimated -$0.28 by -7.14%, while revenue for the quarter reached $17.24m , beating expectations by +7.39%.
Earnings released on 10 Nov 2025
EPS came in at -$0.32 falling short of the estimated -$0.30 by -6.67%, while revenue for the quarter reached $7.61m , missing expectations by -53.45%.
Earnings released on 30 Jul 2025
EPS came in at -$0.31 falling short of the estimated -$0.29 by -6.90%, while revenue for the quarter reached $8.70m , missing expectations by -11.69%.
Earnings released on 8 May 2025
EPS came in at -$0.29 falling short of the estimated -$0.27 by -7.41%, while revenue for the quarter reached $9.18m , missing expectations by -36.35%.
Earnings released on 4 Mar 2025
EPS came in at $0.17 surpassing the estimated -$0.17 by +200.00%, while revenue for the quarter reached $83.75m , beating expectations by +588.34%.
Earnings released on 12 Nov 2024
EPS came in at -$0.47 falling short of the estimated -$0.28 by -67.86%, while revenue for the quarter reached -$7.68m , missing expectations by -129.99%.
Earnings released on 8 Aug 2024
EPS came in at -$0.25 falling short of the estimated -$0.21 by -19.05%, while revenue for the quarter reached $19.69m , missing expectations by -19.06%.
Earnings released on 9 May 2024
EPS came in at -$0.24 falling short of the estimated -$0.21 by -14.29%, while revenue for the quarter reached $12.54m , missing expectations by -45.37%.
Earnings released on 6 Mar 2024
EPS came in at -$0.15 surpassing the estimated -$0.23 by +34.78%, while revenue for the quarter reached $29.06m , beating expectations by +46.30%.
Earnings released on 9 Nov 2023
EPS came in at $0.07 surpassing the estimated -$0.18 by +138.89%, while revenue for the quarter reached $49.21m , beating expectations by +147.80%.
Earnings released on 3 Aug 2023
EPS came in at -$0.20 surpassing the estimated -$0.33 by +39.39%, while revenue for the quarter reached $22.11m , beating expectations by +178.41%.
Earnings released on 3 May 2023
EPS came in at -$0.27 falling short of the estimated -$0.04 by -575.00%, while revenue for the quarter reached $12.93m , missing expectations by -60.01%.
Earnings released on 22 Mar 2023
EPS came in at -$0.47 falling short of the estimated -$0.41 by -14.63%, while revenue for the quarter reached $1.24m , missing expectations by -82.45%.
Earnings released on 10 Nov 2022
EPS came in at -$0.42 surpassing the estimated -$0.50 by +16.00%, while revenue for the quarter reached $285.00k , missing expectations by -96.52%.
Earnings released on 11 Aug 2022
EPS came in at -$0.62 falling short of the estimated -$0.56 by -10.71%, while revenue for the quarter reached $375.00k , missing expectations by -90.22%.
Earnings released on 12 May 2022
EPS came in at -$0.62 falling short of the estimated -$0.56 by -10.71%, while revenue for the quarter reached $1.75m , missing expectations by -54.63%.
Earnings released on 3 Mar 2022
EPS came in at -$0.61 falling short of the estimated -$0.51 by -19.61%, while revenue for the quarter reached $1.77m , missing expectations by -88.82%.
Earnings released on 10 Nov 2021
EPS came in at -$0.12 surpassing the estimated -$0.63 by +80.95%, while revenue for the quarter reached $36.42m , missing expectations by -38.70%.
Earnings released on 5 Aug 2021
EPS came in at -$0.78 falling short of the estimated -$0.64 by -21.88%, while revenue for the quarter reached $2.78m , missing expectations by -71.64%.
WVE Stock Performance
Access detailed WVE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
